Skip to main content
SpringerLink
Log in

Oncologic control provided by HIFU therapy as single treatment in men with clinically localized prostate cancer

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Objective

To assess the long term oncologic results of high-intensity focused ultrasound therapy (HIFU) as a primary and single treatment for clinically localized prostate cancer.

Methods

A total of 119 patients with clinically localized prostate cancer underwent HIFU (Ablatherm®, EDAP, France) as first-line treatment and were retrospectively reviewed. They were stratified according to risk groups proposed by D’Amico. No patient had undergone previous hormonal therapy. PSA level was monitored at 3, 6, 12, 18, 24 months and then yearly. According to the latest ASTRO criteria, failure was defined by a PSA rise of 2 ng/ml or more above the PSA nadir. The biochemical-free survival rate (BFSR) was calculated.

Results

Mean patient age was 68 ± 7.8 years (46–83). Mean follow-up was 3.9 years (1–6.8). Overall 52 patients (43.7%) experienced a biochemical recurrence which included 26, 23 and 3 patients in the low, intermediate and high-risk groups, respectively. In univariate and multivariate analyses, there was a statistical association between preoperative PSA value > 10, a nadir PSA value > 1 and the risk of biochemical recurrence (P < 0.05). The 5-year BFSR rate was 30% with no statistical difference between low- and intermediate-risk patients. None of the 119 patients died of prostate cancer.

Conclusion

High-intensity focused ultrasound therapy provides efficient oncologic control only in patients with low-risk prostate cancer. However, our data could be used to improve the selection of patients who are potential candidates for HIFU therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Boyle P, Severi G, Giles GG (2003) The epidemiology of prostate cancer. Urol Clin North Am 30:209–217

    Article  PubMed  Google Scholar 

  2. Oliver SE, May MT, Gunnell D (2001) International trends in prostate-cancer mortality in the “PSA ERA”. Int J Cancer 92:893–898

    Article  PubMed  CAS  Google Scholar 

  3. Walsh PC, DeWeese TL, Eisenberger MA (2007) Clinical practice. Localized prostate cancer. N Engl J Med 357:2696–2705

    CAS  Google Scholar 

  4. Chaussy C, Thuroff S (2001) Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J Endourol 15:437–440 discussion 447–448

    Article  PubMed  CAS  Google Scholar 

  5. Vallancien G, Prapotnich D, Cathelineau X, Baumert H, Rozet F (2004) Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 171:2265–2267

    Article  PubMed  Google Scholar 

  6. Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C et al (2007) First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 53(6):1194–1203

    Article  PubMed  Google Scholar 

  7. Blana A, Walter B, Rogenhofer S, Wieland WF (2004) High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 63:297–300

    Article  PubMed  Google Scholar 

  8. Gelet A, Chapelon JY, Bouvier R, Rouviere O, Lyonnet D, Dubernard JM (2001) Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol 40:124–129

    Article  PubMed  CAS  Google Scholar 

  9. Ganzer R, Rogenhofer S, Walter B, Lunz JC, Schostak M, Wieland WF et al (2007) PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. Eur Urol 53(3):547–553

    Article  PubMed  Google Scholar 

  10. Poissonnier L, Chapelon JY, Rouviere O, Curiel L, Bouvier R, Martin X et al (2007) Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 51:381–387

    Article  PubMed  CAS  Google Scholar 

  11. D’Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D (2002) Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20:4567–4573

    Article  PubMed  Google Scholar 

  12. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974

    PubMed  Google Scholar 

  13. Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A (2006) Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 97:56–61

    Article  PubMed  Google Scholar 

  14. Rebillard X, Davin JL, Soulie M (2003) Treatment by HIFU of prostate cancer: survey of literature and treatment indications. Prog Urol 13:1428–1456

    PubMed  Google Scholar 

  15. Rebillard X, Soulie M, Chartier-Kastler E, Coulange C, Davin J, Moreau J et al (2008) High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int 101:1205–1213

    Article  PubMed  Google Scholar 

  16. Lee HM, Hong JH, Choi HY (2006) High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 9:439–443

    Article  PubMed  CAS  Google Scholar 

  17. Gulley JL, Figg WD, Steinberg SM, Carter J, Sartor O, Higano CS et al (2005) A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 173:1567–1571

    Article  PubMed  CAS  Google Scholar 

  18. Thuroff S, Chaussy C, Vallancien G, Wieland W, Kiel HJ, Le Duc A et al (2003) High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 17:673–677

    Article  PubMed  Google Scholar 

  19. Chaussy C, Thuroff S (2000) High-intensity focused ultrasound in prostate cancer: results after 3 years. Mol Urol 4:179–182

    PubMed  CAS  Google Scholar 

  20. Chaussy C, Thuroff S (2003) The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 4:248–252

    Article  PubMed  Google Scholar 

  21. Murat FJ, Poissonnier L, Pasticier G, Gelet A (2007) High-intensity focused ultrasound (HIFU) for prostate cancer. Cancer Control 14:244–249

    PubMed  Google Scholar 

Download references

Acknowledgments

The authors want to thank kindly Mathieu Coudert who performed the statistical part of this work at the Department of Statistics, Faculté de Médecine Pierre et Marie Curie, Pitié-Salpétrière Hospital, University Paris 6, Paris, France.

Conflict of interest statement

There is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology of Pitié-Salpétrière Hospital, Groupe Hospitalo-Univeristaire EST, Assistance Publique-Hôpitaux de Paris; Faculté de Médecine Pierre et Marie Curie, University Paris VI, Paris, France

    Vincent Misraï, Morgan Rouprêt, Emmanuel Chartier-Kastler, Alain Haertig, Marc-Olivier Bitker, François Richard & Pierre Conort

  2. Department of Pathology of Pitié-Salpétrière Hospital, Groupe Hospitalo-Univeristaire EST, Assistance Publique-Hôpitaux de Paris; Faculté de Médecine Pierre et Marie Curie, University Paris VI, Paris, France

    Eva Comperat

  3. Department of Radiology of Pitié-Salpétrière Hospital, Groupe Hospitalo-Univeristaire EST, Assistance Publique-Hôpitaux de Paris; Faculté de Médecine Pierre et Marie Curie, University Paris VI, Paris, France

    Raphaële Renard-Penna

  4. Academic Urology Department, Hopital Pitié, 47-83 Boulevard de l’Hôpital, 75013, Paris, France

    Emmanuel Chartier-Kastler

Authors
  1. Vincent Misraï
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Morgan Rouprêt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emmanuel Chartier-Kastler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eva Comperat
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raphaële Renard-Penna
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alain Haertig
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marc-Olivier Bitker
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. François Richard
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Pierre Conort
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emmanuel Chartier-Kastler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Misraï, V., Rouprêt, M., Chartier-Kastler, E. et al. Oncologic control provided by HIFU therapy as single treatment in men with clinically localized prostate cancer. World J Urol 26, 481–485 (2008). https://doi.org/10.1007/s00345-008-0286-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-008-0286-8

Keywords

Search

Navigation